OPDIVO®✦(nivolumab) +relatlimab are in combo phase 2 trial (pointy end).
PD-L1 and anti-lag 3 - solid tumours:-
NCT01968109
Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy.
NSCLC and melanoma that HAVE previously been treated with immunotherapy.
IMO - if any of the 20 BMS trials with relatlimab currently ongoing, show good signs of safety (given)/efficacy then enter stage left - efti.....
Ann: Phase II study for eftilagimod alpha in COVID-19 advances, page-62
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.5¢ | 29.5¢ | $1.339M | 4.459M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 70497 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 15625 | 1 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |